Skip to main content

Table 3 Associations of both coronary artery disease and high-sensitivity cardiac troponin T with major adverse cardiovascular events

From: Combined evaluation of coronary artery disease and high-sensitivity cardiac troponin T for prediction of adverse events in patients with hypertrophic cardiomyopathy

 

NCA, normal hs-cTnT (n = 54)

CAD, normal hs-cTnT (n = 23)

NCA, elevated hs-cTnT (n = 53)

CAD, elevated hs-cTnT (n = 32)

MACEs (n)

5

2

7

10

Person-years

246.8

90.4

199.3

95.8

Incidence rate (95% CI)a

2.0 (0.3–3.8)

2.2 (0.0–5.2)

3.5 (1.0–6.1)

10.4 (4.3–16.6)

Unadjusted HR (95% CI), P

1

1.1 (0.2–5.7), 0.908

1.9 (0.6–6.0), 0.287

5.5 (1.8–16.8), 0.003

Adjusted HR (95% CI), P

Model 1

1

0.6 (0.1–3.3), 0.526

1.6 (0.5–5.2), 0.436

3.4 (1.0–11.1), 0.044

Model 2

1

0.5 (0.1–3.4), 0.521

1.6 (0.5–5.1), 0.461

3.7 (1.0–13.1), 0.046

Model 3

1

0.6 (0.1–4.6), 0.664

1.9 (0.5–7.1), 0.322

5.7 (1.3–24.1), 0.018

Model 4

1

0.5 (0.1–3.9), 0.542

1.2 (0.3–5.2), 0.765

Model 1 with adjustment for age and gender5.0 (1.0–23.8), 0.046

  1. Model 1 with adjustment for age and gender
  2. Model 2 with adjustment for model 1 plus symptoms and comorbidities, including chest pain, palpitations, syncope/pre-syncope, dyspnea, hypertension, diabetes and atrial fibrillation
  3. Model 3 with adjustment for model 2 plus devices, procedures and medications, including aspirin, warfarin, statins and beta-blocker
  4. Model 4 with adjustment for model 3 plus echocardiographic parameters, including LVEDD, LA diameter, MWT, LVEF and LVOT obstruction
  5. CI confidence interval, HR hazard ratio; other abbreviations as in Tables 1 and 2
  6. aPer 100 person-years